Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine. Founded by experts in the fields of genetic medicine and RNA development and delivery, we have a dynamic operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $270M
Founded date: 2022
Investors 2
| Date | Name | Website |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | Newpath Ma... | newpath.pa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.04.2023 | Series A | $270M | iGlobe Par... |
Mentions in press and media 5
| Date | Title | Description |
| 13.10.2025 | Американская фармкомпания Bristol Myers покупает Orbital Therapeutics за $1,5 млрд | Сделка расширяет портфель CAR T-клеточных иммунотерапий Bristol Myers за счет ведущего экспериментального препарата Orbital — OTX-201, предназначенного для лечения аутоиммунных заболеваний. Это первое крупное приобретение компании в этом го... |
| 26.04.2023 | Orbital Therapeutics Raises $270M in Series A Financing | Orbital Therapeutics, a Cambridge, MA-based company focused on developing RNA-based medicines to treat human diseases, raised $270M in Series A funding. The round was led by ARCH Venture Partners, with participation from initial investors a... |
| 26.04.2023 | Orbital Therapeutics Raises $270M to Bring RNA-Based Medicines to New Heights | RNA research has come a long way, leading to commercialized vaccines and a growing list of therapies in development. But this work just scratches the surface of how RNA can transform medicine, according to Giuseppe Ciaramella, co-founder an... |
| 26.04.2023 | Investing in Orbital Therapeutics | “The fact that proteins are not synthesized directly on genes demands the existence of an intermediate information carrier…which receives genetic information from the gene in the form of an unstable intermediate…a special type of RNA molecu... |
| - | Orbital Therapeutics | “Home - Orbital” |